Rilzabrutinib

Rilzabrutinib, a BTK inhibitor, showed significant efficacy in ITP patients, with 65% achieving platelet response vs. 33% on placebo. The study met primary and secondary endpoints, including durable platelet response, reduced bleeding, and improved quality of life. Rilzabrutinib is under regulatory review in the US and EU.

Rilzabrutinib, a BTK inhibitor, showed significant efficacy in ITP patients, with 65% achieving platelet response vs. 33% on placebo. The study demonstrated durable platelet response, reduced bleeding, and improved quality of life, positioning rilzabrutinib as a potential first-in-class treatment for ITP.

Rilzabrutinib, a BTK inhibitor, showed significant efficacy in a Phase 3 study for ITP, achieving platelet response in 65% of patients vs. 33% on placebo. It met primary and secondary endpoints, including durable platelet response, reduced bleeding, and improved quality of life. The safety profile was consistent with previous studies, with mild/moderate AEs like diarrhea and nausea. Rilzabrutinib is under regulatory review in the US and EU.

Sanofi’s rilzabrutinib and Alvotech/Advanz Pharma’s golimumab (AVT05) are among five new entries on the European Medicines Agency’s latest monthly list of products under review. Both drugs are investigational and unapproved globally.

The article discusses the importance of enabling JavaScript for optimal app performance.

DelveInsight's report on Thrombocytopenia Market (2034) covers epidemiology, market trends in the US, EU4, UK, and Japan, highlighting the US as the largest market. Key companies include Sanofi, Principia Biopharma, Baxalta, Takeda, and others. Promising therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, and Nipocalimab are noted. Clinical trials by Qidong Gaitianli Medicines, Karyopharm Therapeutics, Janssen Research & Development, and Amgen are scheduled for June 2024. Marketed drugs like ADZYNMA (Takeda) and TAVALISSE (Rigel Pharmaceuticals/Kissei Pharmaceutical) are discussed. Emerging drugs like Rilzabrutinib (Sanofi/Principia Biopharma) are in Phase III for ITP treatment.

DelveInsight's 'Severe Asthma Pipeline Insight 2024' highlights 40+ companies developing 50+ therapies, including promising candidates like KN-002, BAT2606, CM326, and others. Key companies include Kinaset Therapeutics, GlaxoSmithKline, Sanofi, and AstraZeneca. Recent milestones include positive phase III results for GSK's depemokimab and phase IIb data for Sanofi's rilzabrutinib. The report covers global pipeline, therapeutic assessments, and key insights on severe asthma treatment.

Sanofi reports 15.7% Q3 sales growth, driven by vaccine sales and strong business performance, raising 2024 EPS guidance. Dupixent sales up 23.8%, with full-year target confirmed at €13 billion. Pharma launches grew 67.1%, led by ALTUVIIIO, Nexviazyme, and Rezurock. Vaccines sales increased 25.5%, boosted by flu sales and Beyfortus. Opella sales rose 7.9%, supported by Qunol acquisition. R&D expenses grew 12.7%, while SG&A expenses grew 6.4%. Business EPS at €2.86, up 12.2% reported and 17.6% at CER. Four regulatory approvals and four positive phase 3 data readouts achieved. Negotiations underway to transfer a controlling stake of Opella to CD&R. 2024 business EPS guidance upgraded to low single-digit growth at CER.